Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

Biogen BIIB will report second-quarter 2025 results on July 31, before market open. In the last reported quarter, the company's earnings missed expectation by 7.4%. The Zacks Consensus Estimate for ...

Our Final Take Obviously, Biogen is in the business of making money. It would not have offered to buy Sage at $7.22 a share if it did not believe it would be attractive to Biogen's shareholders.

The collaboration between Biogen and Sage dates to 2020. Biogen committed $1.5 billion up front to begin the R&D alliance focused on depression and movement disorders. Results have been disappointing.

TipRanks Jan. 13, 2025, 08:40 AM BMO Capital says Biogen (BIIB) is looking for an early potential deal by offering to buy Sage Therapeutics (SAGE) for $7.22 per share.

Biogen has offered to acquire all of the outstanding shares of Sage Therapeutics, which it doesn't already own, for $7.22 per share. Biogen currently holds a 10.2% stake in Sage, according to a ...

Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the ...

Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the company. Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. Read more here.

Biogen Inc. BIIB submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. SAGE that it does not already owned by Biogen for $7.22 per share. Goldman Sachs ...

After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. has received an acquisition offer from fellow Cambridge drugmaker Biogen.